Literature DB >> 19237187

Precursors to pelvic serous carcinoma and their clinical implications.

Ann K Folkins1, Elke A Jarboe, Michael H Roh, Christopher P Crum.   

Abstract

Pelvic serous carcinoma has traditionally been viewed as a rapidly evolving malignancy, due principally to its late stage at diagnosis and tendency for poor outcome, both in the endometrium and the upper genital tract. Recently, studies of women with BRCA1 or BRCA2 mutations (BRCA+) undergoing risk reducing salpingo-oophorectomy have highlighted the distal fallopian tube as a common (80%) site of tumor origin and additional studies of unselected women with pelvic serous carcinoma have demonstrated that serous tubal intraepithelial carcinoma may precede a significant percentage of these tumors. This review examines the serous carcinogenic spectrum in the fallopian tube, highlighting recent evidence that these tumors may follow a defined precursor that has been present for a prolonged interval. The data supporting a candidate precursor, the implications of these findings for early detection and prevention of pelvic serous carcinoma and the caveats, are discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19237187     DOI: 10.1016/j.ygyno.2009.01.013

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  43 in total

Review 1.  Protein biomarkers of ovarian cancer: the forest and the trees.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Future Oncol       Date:  2012-01       Impact factor: 3.404

2.  The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma.

Authors:  Elisabetta Kuhn; Robert J Kurman; Robert A Soslow; Guangming Han; Ann Smith Sehdev; Patrick J Morin; Tian-Li Wang; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

3.  The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

4.  Should Fallopian Tubes Be Removed During Hysterectomy Procedures? - A Statement by AGO Ovar.

Authors:  M Pölcher; S Hauptmann; C Fotopoulou; B Schmalfeldt; I Meinhold-Heerlein; A Mustea; I Runnebaum; J Sehouli
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

5.  Primary culture and immortalization of human fallopian tube secretory epithelial cells.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  Nat Protoc       Date:  2012-08-30       Impact factor: 13.491

6.  Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary.

Authors:  Koah R Vierkoetter; Asia R Ayabe; Maya VanDrunen; Hyeong Jun Ahn; David M Shimizu; Keith Y Terada
Journal:  Gynecol Oncol       Date:  2014-08-02       Impact factor: 5.482

7.  Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Joanne Kotsopoulos; Jan Lubinski; Jacek Gronwald; Cezary Cybulski; Rochelle Demsky; Susan L Neuhausen; Charmaine Kim-Sing; Nadine Tung; Susan Friedman; Leigha Senter; Jeffrey Weitzel; Beth Karlan; Pal Moller; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2014-12-18       Impact factor: 7.396

8.  Ovarian cancer pathogenesis: a model in evolution.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  J Oncol       Date:  2009-09-06       Impact factor: 4.375

9.  MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.

Authors:  Cheng-Han Lee; Subbaya Subramanian; Andrew H Beck; Inigo Espinosa; Janine Senz; Shirley X Zhu; David Huntsman; Matt van de Rijn; C Blake Gilks
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

10.  Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis.

Authors:  K Levanon; V Ng; H Y Piao; Yi Zhang; M C Chang; M H Roh; D W Kindelberger; M S Hirsch; C P Crum; J A Marto; R Drapkin
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.